TY - JOUR
T1 - Chronic intrathecal baclofen administration in severe spasticity
AU - Broseta, J.
AU - Garcia-March, G.
AU - Sánchez-Ledesma, M. J.
AU - Anaya, J.
AU - Silva, I.
N1 - Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 1990
Y1 - 1990
N2 - On the basis of previous experimental and clinical studies, 14 patients with severe spasticity due to central or spinal cord damage, resistant to all conservative treatments, were selected after a percutaneous trial period for chronic intrathecal baclofen infusion by programmable pumps. The agent was delivered at C4 in quadriplegic patients or in cases with central spasticity and in the neighbouring areas on the affected segments in paraplegic patients. The daily baclofen dose varied from 25 to 260 pg and was infused in a bolus, continuously infused or both combined according to the results during the trial period. After a mean follow-up period of 11 months, constant decrease of rigidity, absence of spasms, improvement of bladder function, cramping pain remission, and moderate improvement in walking capacity and transfer activities were usually observed. Neither complications nor side effects were noted.
AB - On the basis of previous experimental and clinical studies, 14 patients with severe spasticity due to central or spinal cord damage, resistant to all conservative treatments, were selected after a percutaneous trial period for chronic intrathecal baclofen infusion by programmable pumps. The agent was delivered at C4 in quadriplegic patients or in cases with central spasticity and in the neighbouring areas on the affected segments in paraplegic patients. The daily baclofen dose varied from 25 to 260 pg and was infused in a bolus, continuously infused or both combined according to the results during the trial period. After a mean follow-up period of 11 months, constant decrease of rigidity, absence of spasms, improvement of bladder function, cramping pain remission, and moderate improvement in walking capacity and transfer activities were usually observed. Neither complications nor side effects were noted.
UR - http://www.scopus.com/inward/record.url?scp=0025222296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025222296&partnerID=8YFLogxK
U2 - 10.1159/000100205
DO - 10.1159/000100205
M3 - Research Article
C2 - 1964241
AN - SCOPUS:0025222296
SN - 1011-6125
VL - 54
SP - 147
EP - 153
JO - Stereotactic and Functional Neurosurgery
JF - Stereotactic and Functional Neurosurgery
IS - 1-8
ER -